Oestrogen receptor variants and mutations in human breast cancer

Annals of Medicine

Volumn 29, Issue 3, 1997, Pages 221-234

  Murphy, Leigh C ^a   Leygue, Etienne ^a   Dotzlaw, Helmut ^a   Douglas, Deborah ^a   Coutts, Amanda ^a   Watson, Peter H ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Breast cancer; Mutations; Oestrogen receptor

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELL LINE; EXON; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; HUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW;

EID: 0030801460     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899708999340     Document Type: Review

References (82)

1. Vorherr H (ed.). Breast Cancer. Baltimore: Urban and Schwarzenberg, 1980.
2. Ham J, Parker MG. Regulation of gene expression by nuclear hormone receptors. Curr Opin Cell Biol 1989; 1: 503-11.
3. Tsai M-J, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily. Annu Rev Biochem 1994; 63: 451-86.
4. Kumar V, Green S, Stack G, Berry M, Jin J, Chambon R Functional domains of the human estrogen receptor. Cell 1987; 51: 941-51.
5. Tora L, White J, Brou C, et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 1989; 59: 477-87.
6. Tzukerman MT, Esty A, Santiso-Mere D, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994; 8: 21-30.
7. Montano MM, Muller V, Trobaugh A, Katzenellenbogen BS. The carboxyterminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogens antagonists. Mol Endocrinol 1995; 9: 814-25.
8. Khan SA, Rogers M, Obando JA, Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 1994; 54: 993-7.
9. Schmitt FC. Multistep progression from an oestrogen dependent growth towards an autonomous growth in breast carcinogenesis. Eur J Cancer 1995; 12: 2049-52.
10. Murphy. LC. Mechanisms associated with the progression of breast cancer from hormone dependence to independence. Pezcoller Foundation J 1995; 6: 6-16.
11. Wang Y, Miksicek RJ. Identification of a dominant negative form of the estrogen receptor. Mol Endocrinol 1991; 5: 1707-15.
12. Pfeffer U, Fearotta E, Catagnetta L, Vidali G. Estrogen receptor variant messenger RNA lacking exon 4 in estrogen responsive human breast cancer cell lines. Cancer Res 1993; 53: 741-3.
13. Fuqua SAW, Fitzgerald SD, Chamness GC, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991; 51: 105-9.
14. Miksicek R, Lei Y, Wang Y. Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells. Breast Cancer Res Treat 1993; 26: 163-74.
15. Fuqua SAW, Fitzgerald SD, Allred DC, et al. Inhibition of the estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 1992; 52: 483-6.
16. Leygue ER, Watson PH, Murphy LC. Estrogen receptor variants in normal human mammary tissue. J Natl Cancer Inst 1996; 88: 284-90.
17. Gotteland M, Desauty G, Delarue JC, Liu L, May E. Human estrogen receptor messenger RNA variants in both normal and tumor tissues. Mol Cell Endocrinol 1995; 112: 1-13.
18. Pfeffer U, Fecarotta E, Vidali G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res 1995; 55: 2158-65.
19. R-1 compared to the parental MCF-7 cell line. Mol Cell Endocrinol 1995; 109: 197-207.
20. Leygue E, Huang A, Murphy LC, Watson PH. Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res 1996; 56: 4324-7.
21. CO cells, genetically unstable and containing estrogen receptor mutations are a model for the progression of breast cancers to hormone resistance. Cancer Res 1990; 50: 6208-17.
22. Karnik PS, Kulkarni S, Lui XP, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994; 54: 349-53.
23. Daffada A, Dowsett M. Tissue-dependent expression of a novel splice variant of the human oestrogen receptor. J Steroid Biochem Mol Biol 1995; 55: 413-21.
24. Murphy LC, Dotzlaw H. Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 1989; 3: 687-93.
25. Dotzlaw H, Alkhalaf M, Murphy LC. Characterization of estrogen receptor variant mRNAs from human breast cancers. Mol Endocrinol 1992; 6: 773-85.
26. Murphy LC, Wang M, Courts A, Dotzlaw H. Novel mutations in the estrogen receptor messenger RNA in human breast cancers. J Clin Endocrinol Metab 1996; 81: 1420-7.
27. Pink JJ, Wu SQ, Wolf DM, Bilimoria MM, Jordan VC. A novel 80 KDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res 1996; 24: 962-9.
28. Wang M, Dotzlaw H, Fuqua SAW, Murphy LC. A point mutation in the human estrogen receptor gene is associated with the expression of an abnormal estrogen receptor mRNA containing a 69 novel nucleotide insertion. Breast Cancer Res Treat (in press).
29. Roodi N, Bailey R, Kao WY, et al. Estrogen receptor gene analysis in estrogen positive and receptor negative primary breast cancer. J Natl Cancer Inst 1995; 87: 446-51.
30. Garcia T, Sanchez M, Cox J, Ross J, Schachter B. Identification of a variant form of the human estrogen receptor with an amino acid replacement. Nucleic Acids Res 1989; 17: 8364.
31. Marci P, Khoriaty G, Lehrer S, Karurunaratne A, Milne C, Schachter BS. Sequence of a human estrogen receptor variant allele. Nucleic Acids Res 1992; 20: 2008.
32. Taylor J, Li Y, You M, Wilcox A, Liu E. B region variant of the estrogen receptor gene. Nucleic Acids Res 1992; 20: 2895.
33. McGuire WL, Chamness GC, Fuqua SAW. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991; 5: 1571-7.
34. Wolf DM, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 1994; 31: 129-38.
35. Catherine WH, Wolf DM, Jordan VC. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 1995; 9: 1053-63.
36. Smith EP, Boyd J, Frank G, et al. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med 1994; 331: 1056-61.
37. Zuppan P, Hall JM, Lee MK, Ponglikitmongkol M, King MC. Possible linkage of the estrogen receptor gene to breast cancer in a family with late-onset disease. Am J Hum Genet 1991; 48: 1065-8.
38. Murphy LC, Dotzlaw H, Hamerton J, Schwarz J. Investigation of the origin of variant, truncated estrogen receptor-like mRNAs identified in some human breast cancer biopsy samples. Breast Cancer Res Treat 1993; 26: 149-61.
39. Leygue E, Murphy LC, Kuttenn F, Watson PH. Triple primer PCR: a new way to quantify truncated mRNA expression. Am J Pathol 1996; 148: 1097-103.
40. Erenburg I, Mira-y-Lopez R, Ossowski L, Schachter BS. Effects of an estrogen receptor splice isoform on mammary cell function. Abstract P2-794. Proceedings of the 10th International Congress of Endocrinology, San Francisco, 1996.
41. Murphy LC, Hilsenbeck SG, Dotzlaw H, Fuqua SAW. Relationship of clone 4 estrogen receptor variant mRNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res 1995; 1: 115-59.
42. Daffada A, Johnston S, Smith I, Detre S, King N, Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res 1995; 55: 288-93.
43. Rea D, Parker MG. Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells. Cancer Res 1996; 56: 1556-63.
44. Castles CG, Fuqua SAW, Klotz D, Hill SM. Expression of a consecutively active estrogen receptor variant in the estrogen receptor negative BT-20 human breast cancer cell line. Cancer Res 1993; 53: 5934-9.
45. Pink JJ, Jiang S, Fritsch M, Jordan VC. An estrogen independent MCF-7 breast cancer cell line which contains a novel 80 kilodalton estrogen receptor related protein. Cancer Res 1995; 55: 2583-90.
46. Raam S, Robert N, Pappas CA, Tamura H. Defective estrogen receptor in human mammary cancers: their significance in defining hormone dependence. J Natl Cancer Inst 1988; 80: 756-61.
47. Marsigliante S, Baker V, Puddefoot JR, Barker S, Vinson GP. 4S oestrogen receptor isoforms and their distribution in breast cancer samples. J Mol Endocrinol 1991; 7: 205-11.
48. Marsigliante S, Puddefoot JR, Barker S, Gledhill J, Vinson GP. Discrepancies between antibody (EIA) and saturation analysis of oestrogen receptor content in breast tumour samples. J Steroid Biochem Molec Biol 1990; 37: 643-8.
49. Scott GK, Kushner P, Vigne JL, Benz CC. Truncated forms of DNA-binding estrogen receptors in human breast cancer. J Clin Invest 1991; 88: 700-6.
50. Moncharmont B, Ramp G, De Goeij C, Sluyser M. Comparison of estrogen receptors in hormone dependent a hormone independent Grunder strain mouse mammary tumors. Cancer Res 1991; 51: 3843-8.
51. Montgomery PA, Scott GK, Luce MC, Kaufmann M, Benz CC. Human breast tumors containing non-DNA-binding immunoreactive (67 kDa) estrogen receptor. Breast Cancer Res Treat 1993; 26: 181-9.
52. Huang A, Pettigrew N, Watson PH. Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol 1997; 180: 223-7.
53. Huang A, Leygue E, Snell L, Murphy LC, Watson PH. Expression of estrogen receptor variant mRNAs and determination of estrogen receptor status in human breast cancer. Am J Pathol (in press).
54. Rea D, Parker MG. Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells. Cancer Res 1996; 56: 1556-63.
55. Fuqua SAW, Wolf DM. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat 1995; 35: 233-41.
56. Ignar-Trowbridge DM, Ten g CT, Ross KA, Parker MG, Korach KS, McLachlan JA. Peptide growth factors elicit estrogen receptor dependent transcription activation of an estrogen responsive element. Mol Endocrinol 1993; 7: 992-8.
57. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogens 1995; 10: 2435-46.
58. Klotz DM, Castles CG, Fuqua SAW, Spriggs LL, Hill SM. Differential expression of wild-type and variant estrogen receptor mRNAs by stocks of MCF-7 breast cancer cells may account for differences in estrogen responsiveness. Biochem Biophys Res Commun 1995; 210: 609-14.
59. Pfeffer U. Estrogen receptor mRNA variants. Do they have a physiological role? Ann N Y Acad Sci 1996; 784: 304-13.
60. Koehorst SG, Jacobs HM, Thijssen JH, Blankenstein MA. Wild-type and alternatively spliced estrogen receptor messenger RNA in human meningioma tissue and MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 1993; 45: 227-33.
61. Inoue S, Hoshino S-J, Miyoshi M, et al. Identification of a novel isoform of estrogen receptor, a potential inhibitor of estrogen action, in vascular smooth muscle cells. Biochem Biophys Res Commun 1996; 219: 766-72.
62. Koehorst SGA, Cox JJ, Donker GH, et al. Functional analysis of an alternatively spliced estrogen receptor lacking exon 4 isolated from MCF-7 breast cancer cells and meningioma tissue. Mol Cell Endocrinol 1994; 101: 237-45.
63. Fuqua SAW, Allred DC, Elledge RM, et al. The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat 1993; 26: 191-202.
64. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression, and homology to v-erb-A. Nature 1986; 320: 134-9.
65. Garcia T, Lehrer S, Bloomer W, Schachter B. A variant estrogen receptor messenger ribonucleic acid with reduced levels of estrogen binding in human mammary tumors. Mol Endocrinol 1988; 2: 785-91.
66. Lehrer SP, Schmutzler RK, Rabin JM, Schachter BS. An estrogen receptor genetic polymorphism and a history of spontaneous abortion - correlation in women with estrogen receptor positive breast cancer but not in women with estrogen receptor negative breast cancer or in women without cancer. Breast Cancer Res Treat 1993; 26: 175-80.
67. Lehrer S, Rabin J, Stone J, Berkowitz GS. Association of an estrogen receptor variant with increased height in women. Horm Metab Res 1994; 26: 486-8.
68. Lehrer S, Rabin J, Kalir T, Schachter BS. Estrogen receptor variant and hypertension in women. Hypertension 1993; 21: 439-41.
69. Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P. The cloned human estrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 1989; 8: 1981-6.
70. Jiang S-Y, Langan-Fahey S, Stella A, McCague R, Jordan VC. Point mutation of the estrogen receptor (ER) in the ligand binding domain changes the pharmacology of antiestrogen in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Mol Endocrinol 1992; 6: 2167-74.
71. Wooge CH, Nilsson G, Heierson A, McDonnell D, Katzenellenbogen B. Structural requirements for high affinity ligand binding by estrogen receptors: a comparative analysis of truncated and full length estrogen receptors expressed in bacteria, yeast and mammalian cells. Mol Endocrinol 1992; 6: 861-9.
72. Pakdel F, Katzenellenbogen B. Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. J Biol Chem 1992; 267: 3429-37.
73. Fawell SE, Lees JA, White R, Parker MG. Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 1990; 60: 953-62.
74. Beato M. Gene regulation by steroid hormone. Cell 1989; 56: 335-44.
75. Guichon-Mantel A, Loosfelt H, Lescop P, et al. Mechanisms of nuclear localization of the progesterone receptor: evidence for interaction of monomers. Cell 1989; 57: 1147-54.
76. Leslie KK, Tasset D, Horwitz KB. Funcational analysis of a mutant estrogen receptor isolated from T47Dco breast cancer cells. Am J Obstet Gynecol 1992; 166: 1053-61.
77. Yang NN, Venugopalan M, Hardikar S, Galsebrook A. Identification of an estrogen response element activated by metabolites of 17b-estradiol and raloxifene. Science 1996; 273: 1222-5.
78. Gaub MP, Bellard M, Scheure I, Chambon R Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 1990; 63: 1267-76.
79. Krishnan V, Wang X, Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 1994; 269: 15912-7.
80. Sukovich DA, Mukherjee R, Benfield PA. A novel, cell-type-specific mechanism for estrogen receptor-mediated gene activation in the absence of an estrogen-responsive element. Mol Cell Biol 1994; 14: 7134-43.
81. Mosselman S, Polman J, Dijkema R. ERb: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49-53.
82. Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-30.